Evaluation of HPV-16 and HPV-18 genotyping for the triage of women with high-risk HPV+ cytology-negative results

American Journal of Clinical Pathology

Volumn 136, Issue 4, 2011, Pages 578-586

  Wright Jr , Thomas C ^a   Stoler, Mark H ^b   Sharma, Abha ^c   Zhang, Guili ^c   Behrens, Catherine ^c   Wright, Teresa L ^c   Ferenczy, Alexander ^d   Body, B A ^e   Butcher, A ^c   Eisenhut, C ^f   Rao, A ^g   Young, S ^h   Ackerman, R ⁱ   Anders, R ^j   Andruczyk, E ^k   Aqua, K ^l   Black, R ^m   Blank, S ⁿ   Bressman, P ^o   Brody, K ^p   Burigo, J ^q   Chavoustie, S ^r   Davis, M ^s   Donovan, A ^t   Eder, S ^u   Eubank, C ^v   Fehnel, S ^w   Feldman, R ^x   Filosa, R ^y   Fowler, S ^z   Goldberg, C ^aa   Groom, R ^ab   Grube, J ^ac   Grumley, P ^ad   Hadley, P ^ae   Harris, M ^af   Hazan, L ^ag   Huey, J ^ah   Jacobs, M ^ai   Kleinpeter, S ^aj   Lederman, S ^ak   Lenihan Jr , J ^al   Levine, B ^am   Lowder, K ^an   Lurvey, N ^ag   Martin Jr , J ^ao   McDavid, R ^ap   McGettigan, J ^aq   Michelson, J ^ar   Morgan, F ^as   Myers, R ^at   Osman, K ^au   Parker Jr , R ^av   Pollard, J ^aw   Rappleye, A ^ax   Reagan, R ^ay   Reisman, H ^az   Rogers, L ^ba   Sager, N ^bb   Sieggreen, G ^bc   Somerall Jr , W ^bd   Sperling, M ^be   Surowitz, R ^bf   Swor, M ^bg   Trupin, S ^bh   Tydings, A ^bi   Waldrep, K ^bj   Walland, D ^bk,bl   Wilkerson, W ^bm   Wilson, W ^bj   Wininger, S ^bn   Yassear, S ^bo   more..

^a Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^c ROCHE MOLECULAR SYSTEMS   (United States)

^d MCGILL UNIVERSITY   (Canada)

^e LABORATORY CORPORATION OF AMERICA   (United States)

^f DCL Medical Laboratories   (United States)

^g SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^h TRICORE REFERENCE LABORATORIES   (United States)

ⁱ Comprehensive Clinical Trials ^*  (United States)

^j Green Clinic   (United States)

^k Philadelphia Women's Research   (United States)

^l Visions Clinical Research   (United States)

^m Women's Hlth Inst of California   (United States)

ⁿ Mount Vernon Clinical Research   (United States)

^o Tennessee Women's Care   (United States)

^p Chattanooga Medical Research   (United States)

^q OB/GYN Specialists of the Palm Beaches   (United States)

^r Segal Institute for Clinical Research   (United States)

^s SC Clinical Research Center   (United States)

^t Bluegrass Clinical Research   (United States)

^u Delaware Valley OB GYN and Infertility Group   (United States)

^v Advanced Research Associates   (United States)

^w Advanced Clinical Concepts   (United States)

^x MIAMI RESEARCH ASSOCIATES   (United States)

^y Center for Women's Health of Lansdale   (United States)

^z Blue Skies Center for Women   (United States)

^aa Visions Clinical Research   (United States)

^ab Impact Clinical Trials   (United States)

^ac Physicians' Research Options   (United States)

^ad Four Rivers Clinical Research   (United States)

^ae Medical Network for Education and Research   (United States)

^af Women's Health Research   (United States)

^ag Impact Clinical Trials   (United States)

^ah HWC Women's Research Center   (United States)

^ai EAST TEXAS MEDICAL CENTER   (United States)

^aj Mobile OB/GYN   (United States)

^ak Altus Research   (United States)

^al Tacoma Women's Specialists   (United States)

^am Phoenix OB GYN Association   (United States)

^an Woman's Clinic   (United States)

^ao eCast Corporation   (United States)

^ap State of Franklin Healthcare Associates Research   (United States)

^aq Quality of Life Medical and Research Center   (United States)

^ar Eastern Carolina Women's Center   (United States)

^as Tidewater Clinical Research   (United States)

^at St John's Center for Clinical Research   (United States)

^au M and O Clinical Research   (United States)

^av Lyndhurst Gynecologic Associates PA   (United States)

^aw Enterprise Women's Center   (United States)

^ax Salt Lake Informatics Decision Enhancement and Surveillance Center (IDEAS)   (United States)

^ay Women's Clinical Research ^*  (United States)

^az Atlanta North Gynecology   (United States)

^ba Women's Clinical Research   (United States)

^bb Jacksonville Center for Clinical Research   (United States)

^bc Women's OB GYN   (United States)

^bd Clinical Research Consultants   (United States)

^be Edinger Medical Group Clinical Research Center   (United States)

^bf Health Awareness   (United States)

^bg Physician Care Clinical Research   (United States)

^bh Woman's Health Practice   (United States)

^bi Clinical Trials Management   (United States)

^bj Advanced Research Associates   (United States)

^bk Fellows Research Alliance   (United States)

^bl Fellows Research Alliance   (United States)

^bm Women's Care Florida   (United States)

^bn Precision Trials   (United States)

^bo Yassear Clinical Research   (United States)

more..

Author keywords

Adjunct testing; Cervical cancer screening; Cervical intraepithelial neoplasia; Cytology; Genotype; HPV DNA testing; Negative for intraepithelial lesions or malignancy; NILM

Indexed keywords

ADULT; AGED; ARTICLE; BIOPSY TECHNIQUE; CANCER RISK; COLPOSCOPY; EMERGENCY HEALTH SERVICE; FEMALE; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; MAJOR CLINICAL STUDY; NONHUMAN; PAPILLOMAVIRUS INFECTION; PREVALENCE; PRIORITY JOURNAL; SCREENING TEST; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY;

ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; COLPOSCOPY; CROSS-SECTIONAL STUDIES; EARLY DETECTION OF CANCER; FEMALE; GENOTYPE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; MASS SCREENING; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; PREVALENCE; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 80053473495     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPTUS5EXAS6DKZ     Document Type: Article

References (29)

1. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12-19. (Pubitemid 29406813)
2. Schiffman M, Castle PE, Jeronimo J, et al. Human papillomavirus and cervical cancer. Lancet. 2007;370:890-907. (Pubitemid 47371147)
3. Wright TC Jr, Massad LS, Dunton CJ, et al. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol. 2007;197:346-355. (Pubitemid 47464164)
4. Saraiya M, Berkowitz Z, Yabroff KR, et al. Cervical cancer screening with both human papillomavirus and Papanicolaou testing vs Papanicolaou testing alone: what screening intervals are physicians recommending? Arch Intern Med. 2010;170:977-985.
5. Saraiya M, Irwin KL, Carlin L, et al. Cervical cancer screening and management practices among providers in the National Breast and Cervical Cancer Early Detection Program (NBCCEDP). Cancer. 2007;110:1024-1032. (Pubitemid 47312868)
6. Bosch FX, De Sanjose S. Chapter 1: Human papillomavirus and cervical cancer: burden and assessment of causality. J Natl Cancer Inst Monogr. 2003:3-13.
7. De Sanjose S, Diaz M, Castellsague X, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis. 2007;7:453-459. (Pubitemid 46962343)
8. American Society for Colposcopy and Cervical Pathology HPV Genotyping Clinical Update 2009. http://www.asccp.org/consensus.shtml. Accessed February 2011.
9. Stoler MH, Wright TC Jr, Sharma A, et al. High-risk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV study. Am J Clin Pathol. 2011;135:468-475.
10. Kurman RJ, Ellenson LH, Bonnett BM. Blaustein's Pathology of the Female Genital Tract. New York, NY: Springer Verlag; 2011.
11. Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA. 2002;287:2114-2119. (Pubitemid 34437346)
12. Chernick M. Bootstrapping Methods: A Practitioner's Guide. New York, NY: Wiley Interscience; 1999:8, 112.
13. cobas HPV Test [package insert]. Pleasanton, CA: Roche Molecular Systems; 2009.
14. The AMPLICOR Human Papillomavirus (HPV) test [package insert]. Pleasanton, CA: Roche Molecular Systems; 2008.
15. Bigras G, De Marval F. The probability for a Pap test to be abnormal is directly proportional to HPV viral load: results from a Swiss study comparing HPV testing and liquid-based cytology to detect cervical cancer precursors in 13,842 women. Br J Cancer. 2005;93:575-581. (Pubitemid 43080002)
16. Cuzick J, Clavel C, Petry KU, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer. 2006;119:1095-1101. (Pubitemid 44116919)
17. Ronco G, Segnan N, Giorgi-Rossi P, et al. Human papillomavirus testing and liquid-based cytology: results at recruitment from the New Technologies for Cervical Cancer randomized controlled trial. J Natl Cancer Inst. 2006;98:765-774. (Pubitemid 43983300)
18. Dillner J, Rebolj M, Birembaut P, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ. 2008;337:a1754. doi:10.1136/bmj.a1754.
19. Kitchener HC, Gilham C, Sargent A, et al. A comparison of HPV DNA testing and liquid based cytology over three rounds of primary cervical screening: extended follow up in the ARTISTIC trial [published online ahead of print February 18, 2011]. Eur J Cancer. doi:10.1016/j.ejca.2011.01.008.
20. Kjaer SK, Frederiksen K, Munk C, et al. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst. 2010;102:1478-1488.
21. Moscicki AM, Schiffman M, Kjaer S, et al. Chapter 5: Updating the natural history of HPV and anogenital cancer. Vaccine. 2006;24(suppl 3):S3/42-S3/51.
22. Wright TC Jr, Stoler MH, Behrens CM, et al. The ATHENA human papillomavirus study: design, methods, and baseline results. Am J Obstet Gynecol. In press.
23. Khan MJ, Castle PE, Lorincz AT, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst. 2005;97:1072-1079. (Pubitemid 41417924)
24. Sawaya GF, Kerlikowske K, Lee NC, et al. Frequency of cervical smear abnormalities within 3 years of normal cytology. Obstet Gynecol. 2000;96:219-223. (Pubitemid 30447342)
25. Kulasingam SL, Hughes JP, Kiviat NB, et al. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. JAMA. 2002;288:1749-1757.
26. Mayrand MH, Duarte-Franco E, Rodrigues I, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med. 2007;357:1579-1588. (Pubitemid 47598400)
27. Sasieni P. Estimating prevalence when the true disease status is incompletely ascertained. Stat Med. 2001;20:935-949. (Pubitemid 32249091)
28. Wright TC Jr, Schiffman M, Solomon D, et al. Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet Gynecol. 2004;103:304-309.
29. Castle PE, Sideri M, Jeronimo J, et al. Risk assessment to guide the prevention of cervical cancer. Am J Obstet Gynecol. 2007;197:356.e1-356.e6. doi:10.1016/j.ajog.2007.07.049.